- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00453908
Alfuzosin Versus Placebo in Acute Urinary Retention (ALF-RIK)
Does Alfuzosin OD vs. Placebo in Male Patients Facilitate Spontaneous Voiding During Clean Intermittent Self-Catheterization Following Acute Urinary Retention?
The primary objective of the study is to investigate if 14 days of treatment with Alfuzosin compared to placebo, will increase the number of patients with satisfying spontaneous voiding after acute urinary retention treated with Clean Self-Catheterization.
Furthermore is investigated the safety of the medical treatment and self-catheterization.
Study Overview
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Hoersholm, Denmark
- Sanofi-Aventis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men with acute urinary retention and catheterized
- Benign hypertrophia of prostate
- Patient is diagnosed in Emergency room or at a acute hospitalization
Exclusion Criteria:
- Known prostate cancer
- Prior urinary retention within 30 days
- Urinary retention occurring in relation to surgery
- Blood in urine
- Difficult or impossible catheterization
- Fever > 38 degree Celsius
- Decreased kidney function
- Permanent catheter > 14 days
- Treatment with alfa 1 blocker within 30 days
- Meeting contraindications to treatment with Alfuzosin
- Treatment with other drugs for urinary problems
The above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Number of patients with satisfying spontaneous voiding after 14 days measured by bladder scan at day 14.
|
Secondary Outcome Measures
Outcome Measure |
---|
Number of days until termination of self catheterization
|
Number of patients with urinary infection requiring treatment
|
Pressure of voiding, volume of voiding, residual urine after voiding, measured by urine culture and bladder scan at day 14.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Henning Andersen, MD, Sanofi
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L_9397
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Retention
-
Rambam Health Care CampusCompleted
-
Mayo ClinicRecruitingPostoperative Urinary RetentionUnited States
-
TriHealth Inc.Completed
-
Lundbeck FoundationCompletedPostoperative Urinary RetentionDenmark
-
University of RochesterTerminatedPost-Operative Urinary RetentionUnited States
-
Rigshospitalet, DenmarkLundbeck FoundationCompletedPostoperative Urinary Retention (POUR)Denmark
-
Anand Rughani, MDMaineHealthCompletedPost-operative Urinary RetentionUnited States
-
Wake Forest University Health SciencesTerminatedUrinary Retention PostoperativeUnited States
-
University of MichiganTerminatedPostoperative Urinary RetentionUnited States
-
Women and Infants Hospital of Rhode IslandAmerican Urogynecologic Society; American Association of Gynecologic LaparoscopistsActive, not recruitingVoiding Disorders | Urinary Retention PostoperativeUnited States
Clinical Trials on Alfuzosin
-
Unity Health TorontoSanofiWithdrawn
-
SanofiCompleted
-
International Bio serviceNot yet recruiting
-
Singapore General HospitalSanofiWithdrawn
-
SanofiCompleted
-
Hospital Authority, Hong KongTerminatedProstatic Hyperplasia | Acute Disease | Urinary RetentionChina
-
Torrent Pharmaceuticals LimitedCompleted
-
University Hospitals Cleveland Medical CenterSanofiCompletedErectile Dysfunction | BPHUnited States
-
SanofiCompletedProstatic Hyperplasia | Urinary Retention | Benign Prostatic HypertrophyUnited States, Canada, Poland, Romania, Australia, Netherlands, Portugal, Spain, Sweden, Bulgaria, Denmark, Finland, Hungary, Norway, South Africa, Greece, Israel